RIMLS highlights 2017
Several awards for Peter van de Kraan and his teamPeter van de Kraan and his team obtained several awards in 2017. In this video, they explain what made them so successful.
Royal decoration for Henk Stunnenberg26 April 2017
Henk Stunnenberg was appointed by His Majesty as Knight in the Order of the Dutch Lion, a highly prestigious decoration.
Henk Stunnenberg's research aims to unravel the molecular basis of development and differentiation emanating from the genome and epigenome in the context of health and disease. His group employs state-of-the-art technological developments ranging from single molecule studies through to genome wide elucidation of genetic and epigenetic pathways.
Henk Stunnenberg is full professor, head of the Department of Molecular Biology and member of RIMLS. He was also the coordinator of the large H2020 project BLUEPRINT that aimed at generating at least 100 reference epigenomes and studying these, to increase our understanding of underlying processes of health and disease. For instance, processes that lie at the origin of illnesses such as blood cancers (leukaemia) and certain types of diabetes. Henk Stunnenberg has published seminal papers in Nature, Science and Cell.
In his field of Molecular Biology, Henk Stunnenberg stands with the best. Stunnenberg’s enthusiasm, broad scientific knowledge, and international reputation draw young scientists from all across the world.
Several prizes for Jolanda de Vries13 January 2017
During the New Years 2017 event of the Radboud university medical center, Jolanda de Vries was honored by Leon van Halder, chairman of our executive board, with the Radboud Medal.
The Radboud Medal is the highest Radboudumc honor awarded annually to a person who has contributed significantly to the objective of the Radboudumc as top knowledge center for academic medicine and health.
Jolanda de Vries, professor of translational tumor immunology, works at the Department of Tumor Immunology. She established a clinical vaccination program in which tumor-associated antigens loaded on DCs are used to treat both melanoma and colon cancer patients. Major current projects are to translate the DC vaccination into various clinical settings. Recently she and her team obtained a budget of 20 million euros from the national basic health insurance to introducte the experimental treatment with a vaccine that reduced the risk of the recurrence of skin cancer. The treatment will be offered in Nijmegen, Amsterdam, Rotterdam and Zwolle and is led by Jolanda de Vries.
12 October 2017
Jolanda de Vries, Department of Tumor Immunology, theme Cancer development and immune defense has been awarded the 2017 Huibregtsen Prize for her work on natural dendritic cell vaccines. This award is given to a research project that is scientifically innovative and benefits society.
Jolanda de Vries investigates the role of dendritic cells in the defence against various forms of cancer and studies the effectiveness of dendritic cell therapy. Dendritic cells play an important role in immune responses. In response to infection or inflammation, and in response to cancer, dendritic cells undergo a complicated maturation process, after which they ultimately present fragments (proteins) from the pathogens or cancer cells to T cells in the lymph nodes. These are the ‘killer cells’ of the immune system. Due to the priming from the dendritic cells, they are able to recognise and attack cancer cells.
About the Huibregtsen Prize (in Dutch).
Film about the research (in Dutch).